Plant ID: NPO25967
Plant Latin Name: Mallotus philippensis
Taxonomy Genus: Mallotus
Taxonomy Family: Euphorbiaceae
NCBI TaxonomyDB:
316645
Plant-of-the-World-Online:
n.a.
Malaysia; Indonesia; India; Thailand
TSHR; | |
GLA; HPRT1; | |
NFKB1; | |
THPO; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
Enzyme_unclassified | HPRT1 | Hypoxanthine-guanine phosphoribosyltransferase | P00492 | CHEMBL2360 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.398E-09 | 3.044E-05 | CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.536E-08 | 1.672E-04 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.155E-07 | 3.016E-03 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.828E-07 | 4.200E-03 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.157E-06 | 4.200E-03 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.667E-06 | 2.293E-02 | CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0032769; negative regulation of monooxygenase activity | 1.059E-05 | 2.306E-02 | GLA, NFKB1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.271E-05 | 2.459E-02 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.639E-05 | 2.549E-02 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.319E-05 | 3.156E-02 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.615E-05 | 3.164E-02 | CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.034E-05 | 4.261E-02 | CYP2C19, CYP2C9 |
CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 3.257E-03 | 6.448E-01 | NFKB1 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 7.311E-03 | 9.690E-01 | CYP2C19, CYP2C9, CYP3A4 |
CC | GO:0043226; organelle | GO:0060205; cytoplasmic vesicle lumen | 1.013E-02 | 1.000E+00 | GLA, NFKB1 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.728E-02 | 1.000E+00 | CYP2C19, CYP2C9, CYP3A4, LMNA |
CC | GO:0044464; cell part | GO:0035578; azurophil granule lumen | 4.162E-02 | 1.000E+00 | GLA |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.289E-07 | 1.808E-05 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.253E-06 | 1.285E-04 | CYP2C9, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.482E-06 | 1.444E-04 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.844E-04 | 3.642E-03 | HPRT1, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.357E-04 | 4.858E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.690E-04 | 4.858E-03 | CYP2C9, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.653E-04 | 5.251E-03 | CYP2C9, CYP3A4 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.436E-03 | 1.260E-02 | CYP2C9, HPRT1, CYP2C19, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.091E-03 | 1.077E-02 | CYP2C9, CYP2C19 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.696E-03 | 1.340E-02 | LMNA, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |